Drug · DIN 02361671
RAPAFLO
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since November 11, 2022; first marketed October 26, 2011.
- Drug Identification Number (DIN)
- 02361671
- Company (DIN owner)
- Allergan IncMarkham, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Silodosin G04CA04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SILODOSIN | 8 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 12, 2018: NOC 20605New Drug Submission (NDS) · Manufacturer name change
- April 5, 2017: NOC 19129New Drug Submission (NDS) · Manufacturer name change
- January 29, 2015: NOC 16581New Drug Submission (NDS) · Merger - buyout
- January 11, 2011: NOC 11994New Drug Submission (NDS)
Other DINs named RAPAFLO
- DIN 02361663 · Cancelled Post Market